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A 42-year-old man attended his primary care physician com-plaining of fatigue. He had a medical history of Coxsackie 
B myocarditis in 2002 from which he had recovered fully as well 
as hypertension. His blood pressure had been well controlled on 
3 agents (furosemide 40 mg daily, amlodipine 10 mg daily, and 
perindopril 8 mg daily). He had no notable family history.
Physical examination was unremarkable, but his blood 
pressure remained consistently elevated at 186/98 mm Hg. 
Routine biochemical investigation revealed new onset of 
hypokalemia (serum potassium, 2.3 mmol/L).
Discussion of Differential Diagnosis
E.M. Freel: What would be the two most likely underlying 
differential diagnoses?
J.A. Staessen: What is the role of diuretic therapy in the 
hypokalemia? And the other question I have as a hypertension 
specialist? Why do you give furosemide?
E.M. Freel: Furosemide was discontinued. His potassium 
was rechecked, and it remained low. That is a very good point. 
In our defense, he came to us as a tertiary referral. We would 
always use thiazide diuretics, particularly in someone with 
normal renal function. His diuretic was changed to a differ-
ent agent to allow subsequent testing off diuretic, I think this 
alternative agent was an α-blocker.
G.L. Jennings: Perhaps the furosemide was a leftover from 
his myocarditis in the past.
E.M. Freel: Possibly. This gentleman has very intermittently 
attended his General Practitioner over the years, and it was a 
historical treatment.
J.P. Granger: Do you have any insight into the renal hemo-
dynamics such as creatinine?
E.M. Freel: It was normal. The only abnormality on his rou-
tine biochemistry was hypokalemia which was new.
M. De Buyzere: What do we know about aldosterone?
E.M. Freel: Nothing yet, but we soon will.
E.L. Schiffrin: You asked for the 2 diagnoses, and nobody 
gave them yet. Primary hyperaldosteronism is one and the 
potential for renal artery stenosis that could also be associated 
with hyperaldosteronism and hypokalemia.
E.M. Freel: Yes.
G.L. Jennings: A third is other forms of secondary hyperal-
dosteronism such as liquorice?
E.M. Freel: Statistically, the most likely causes of this 
gentleman’s hypertension are primary aldosteronism or renal 
vascular disease.
Further Discussion of Differential Diagnosis
Thus, there was strong clinical suspicion of primary aldoste-
ronism or renal artery stenosis as a cause for his worsening 
hypertension and hypokalemia. However, both plasma renin 
concentration and plasma aldosterone were suppressed which 
would effectively exclude both conditions.
Other causes of mineralocorticoid hypertension were con-
sidered and are outlined in the Table. There was no clinical 
evidence of Cushing syndrome, and screening tests were not 
in keeping with cortisol excess. The lack of family history of 
significant hypertension and previously normal serum potas-
sium made a rare genetic disorder such as Liddle syndrome, 
in which constitutive opening of the renal epithelial sodium 
channel leads to chronic sodium retention and urinary potas-
sium excretion leading to hypertension and hypokalemia less 
likely but not impossible.
Next Diagnostic Steps
E.M. Freel: I welcome some suggestions from the audience as 
to what investigation they would recommend now. Perhaps to 
exclude the unlikely but possible diagnoses: 11β-hydroxylase 
deficiency, 17α-hydroxylase deficiency, syndrome of apparent 
mineralocorticoid excess.
M. De Buyzere: Were there data on 24-hour urinary cortico-
steroids? Or was there imaging of the adrenals?
E.M. Freel: That is exactly right. It was very important that 
we performed a 24-hour urine collection to look at this gentle-
man’s multisteroid profile and look at his urinary corticoste-
roid biosynthetic pathway. So that is exactly what we did.
A 24-hour urine was performed for assessment of pro-
duction of corticosteroids and their precursors by gas chro-
matography–mass spectrometry. Figure 1 illustrates the 
corticosteroid biosynthetic pathway in the adrenal cortex and 
demonstrates (yellow boxes) that this patient had elevated 
mineralocorticoid precursors deoxycortisol, deoxycorticoste-
rone, and corticosterone.
The abnormal steroids were not in a pattern characteris-
tic of rare genetic disorders in which enzyme deficiencies 
such as 11β-hydroxylase and 17α-hydroxylase results in 
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mineralocorticoid hypertension attributable to elevated mineralo-
corticoid precursors. Therefore, the only other explanation was 
that there was disordered adrenal architecture such as an adrenal 
tumor, and so a computed tomographic scan of the adrenal glands 
was requested.
Confirmation of Diagnosis
The adrenal computed tomographic scan (Figure 2) demon-
strated a 7-cm heterogeneous left adrenal mass characteristic 
of adrenocortical carcinoma (ACC).
E.L. Schiffrin: So, when one has such an abnormal produc-
tion of metabolites by the adrenals, should one think specifi-
cally of some type of tumor?
E.M. Freel: Essentially yes, unless the patient in question 
was a neonate, in which case an inborn or congenital abnor-
mality listed above would be likely. But an adult patient pre-
senting with this very odd pattern, it’s really only going to be 
an abnormality of architecture.
E.L. Schiffrin: What you mean by that is that it is not a 
benign tumor.
E.M. Freel: That is entirely true. And that is confirmed by 
the radiological appearance of this tumor which by size alone 
would suggest malignancy. Benign tumors tend to be <4 cm.
Surgical Treatment
The patient underwent left adrenalectomy and nephrectomy 
in May 2012. Histopathology confirmed ACC with clear exci-
sion margins, no involvement of excised lymph nodes, and an 
intact adrenal capsule. Hence, the tumor was staged as pT2 N0 
M0. Malignancy was confirmed using the original Weiss crite-
ria1 in which the presence of 3 positive features are required to 
confirm malignancy; this tumor had 6 positive features.
P. O’Dwyer: You may wonder why we took out this gentle-
man’s kidney. The computed tomographic scan didn’t show 
you that his vascular pedicle is involved with this tumor. He 
also has a premalignant lesion in his kidney. So, he had 2 good 
reasons for a laparoscopic adrenalectomy and nephrectomy. 
The tumor is ≈12 × 8 cm.
E.M. Freel: Would it be worth commenting on laparoscopic 
versus open adrenalectomy in this situation with a big tumor 
and a malignancy?
P. O’Dwyer: We attempt laparoscopic adrenalectomy on 
everybody and the reason for that is both the view you get, 
particularly on the right side you can operate much better on 
the right-hand side than doing an open. A very large one on 
the right-hand side required thoracoabdominal incision to get 
you the same access to a large right adrenal tumor. But lapa-
roscopically, we can mobilize it and put it up over the right 
lobe of the liver. The cava is the key thing. If you are doing 
that in open surgery, you are using your hand and these are 
necrotic tumors and it is quite easy to perforate these tumors. 
I don’t think we have perforated any tumor laparoscopically 
because dissection is so much more gentle. More than 400 
Table.  Disorders Associated With Hypertension and 
Hypokalemia and the Corresponding Effects on Plasma Renin 
and Aldosterone Production
Disorder
Plasma 
Renin
Plasma  
Aldosterone
Primary aldosteronism ↓ ↑
Renal artery stenosis ↑ ↑
Renin-secreting tumor ↑ ↑
Liddle syndrome ↓ ↓
Cushing syndrome ↓ ↓
11β-Hydroxylase deficiency ↓ ↓
17α-Hydroxylase deficiency ↓ ↓
Syndrome of apparent 
mineralocorticoid excess
↓ ↓
Figure 1. Corticosteroid biosynthetic 
pathway. Elevated mineralocorticoid 
precursors highlighted in yellow. 3β-
HSD indicates 3-beta-hydroxyeroid 
dehydrogenase; 17βHSD, 17-beta-
hydroxysteroid dehydrogenase; 
11βOH, 11-beta-hydroxylase; DHEA, 
dehydroepiandrosterone; P-450c17, 
17-alpha-hydroxylase; and P-450c21, 
21-hydroxylase.
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adrenalectomies and we haven’t seen a local recurrence yet. 
And 40% of the tumors are >6 cm.
Postoperative Outcome
Within 1 month of surgery, his blood pressure normalized on 
dual therapy (amlodipine 10 mg daily and perindopril 8 mg 
daily) and his plasma potassium also returned to within the 
normal range. A subsequent 24-hour urine steroid profile was 
also normal. He was commenced on the adrenolytic drug, 
Mitotane (Lysodren, o,p′-DDD, a congener of the pesticide 
dichlorodiphenyltrichloroethane) which was well tolerated. 
However, 2 years later, the patient developed an isolated liver 
metastasis which was detected on routine surveillance imag-
ing and resected in early 2014. He remains well and free from 
radiological or biochemical evidence of recurrence.
Adrenocortical Carcinoma
ACC is rare with an incidence of 1 to 2 cases/million per year and 
is more common in women than men (female:male: 1.5–2.5:1). 
Typically, there is a bimodal age distribution, with disease peaks 
before the age of 5 and in the fourth to fifth decade of life; the 
disease is usually more aggressive in adults than in children.2
Approximately 60% of ACC are hormone secreting and so 
may present with a clinical syndrome consistent with cortico-
steroid hormone excess.3 In 45% of cases, the clinical presen-
tation can be consistent with Cushing syndrome (attributable 
to cortisol excess) or, in 25%, a combination of Cushing syn-
drome and androgen excess (leading to virilization). Less than 
10% present with androgen excess alone and ≈1% present 
with aldosterone excess.4 Excess production of 17-deoxyster-
oids of the zona glomerulosa (deoxycorticosterone, corticos-
terone, and 18-hydroxycorticosterone) as a manifestation of 
ACC is rare. There are only a few case reports in the literature, 
and so the exact prevalence is difficult to estimate but cer-
tainly accounts for <1% of all ACC.5
ACC carries a poor prognosis. Five-year survival is ≈45% 
to 60% for early-stage disease (stage I–II) and 10% to 25% 
for advanced stage disease (stage III–IV). Complete surgical 
resection is the only means of cure but is only possible in stage 
I to III disease.6 However, resection is not curative for many, 
probably attributable to the presence of occult micrometastases 
at the time of initial presentation, even with stage I disease. For 
example, in a single-center report of 202 consecutive cases of 
ACC, 40% of patients with stage I to III disease had developed 
distant metastasis 2 years after diagnosis (27%, 46%, and 63% 
of patients with stage I, II, and III disease, respectively).7
Given the aggressiveness of this disease and relatively dis-
appointing surgical outcomes, use of adjuvant therapy is often 
required. In this setting, the most commonly used drug is the 
adrenolytic agent, mitotane (Lysodren, o,p′-DDD, a conge-
ner of the pesticide dichlorodiphenyltrichloroethane ) which 
was used in the case outlined above. Although there is no 
prospective randomized controlled trial of adjuvant mitotane 
treatment in ACC, a retrospective observational study led by 
Terzolo et al8 provides the best evidence of clinical benefit. 
In this study, 3 cohorts of patients from separate centers with 
stage I to III disease underwent surgery with curative intent. 
One cohort was given adjuvant mitotane, and the other two 
were not. Mitotane treatment was associated with a signifi-
cantly longer recurrence-free survival as compared with either 
control group (median recurrence-free survival, 42 versus 
10 and 25 months in the Italian and German control groups, 
respectively). Therefore, use of mitotane for ≤2 years after 
apparently curative surgery for ACC is now standard practice 
although the question of its use in patients with apparently 
low-risk disease is currently being explored in the ADIUVO 
(Efficacy of Adjuvant Mitotane Treatment in Prolonging 
Recurrence-Free Survival in Patients with Adrenocortical 
Carcinoma at Low-Intermediate Risk of Recurrence) study.
There is no curative therapy for recurrent or metastatic 
ACC; however, resection of locally recurrent or distant disease 
may prolong survival in some patients.9–11 This is particularly 
true if the disease-free interval is >12 months as was the case 
with the patient outlined above. It is in the setting of recurrent 
disease that the largest prospective randomized trial of ACC 
to date was undertaken. The First International Randomized 
trial in locally advanced and Metastatic Adrenocortical 
Carcinoma Treatment (FIRM-ACT) trial randomly assigned 
304 patients with advanced ACC not amenable to radical sur-
gery to mitotane plus either combination chemotherapy (eto-
poside, doxorubicin, and cisplatin; EDP) or streptozotocin.12 
There was a significantly prolonged progression-free survival 
in the mitotane–combination chemotherapy group; however, 
this was just 5 versus 2 months in the streptozotocin-treated 
group. Overall, survival was not significantly different (14.8 
months in mitotane–combination chemotherapy, 12 months 
in mitotane–streptozotocin; P=0.07) suggesting that, although 
mitotane–combination chemotherapy was the best chemo-
therapy regime to be offered in advanced/recurrent ACC, the 
prognosis in this setting is dismal.
In summary, hypertension with hypokalemia is statisti-
cally most likely to be attributable to primary aldosteronism 
or renal artery stenosis. In this case, assessment of a baseline 
aldosterone-to-renin ratio should help begin to differentiate 
between these 2 disorders. Suppression of renin and aldoste-
rone, as was the situation in this case, should result in a search 
for more obscure underlying causes of this clinical phenotype.
Figure 2. Computed tomographic scan of abdomen illustrating a 
7-cm left adrenal tumor.
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Final Discussion of Hot Topics in Adrenal Tumors
M. De Buyzere: Two questions. First question is are you aware 
of markers of very bad, a very poor prognosis? I am aware of a 
publication microRNA-210 would be predictive of a very poor 
prognosis. And the second question, there is a European net-
work (European Network for the Study of Adrenal Tumours 
[ENSAT]) when you are faced with an adrenal mass. What do 
you think about these recommendations?
E.M. Freel: In Glasgow, we are members of ENSAT and 
we find this organization to be very useful, particularly in the 
management of incidental adrenocortical masses which we 
see lots of now on routine imaging. They comprise a large 
number of referrals to the endocrine clinic. And again I think 
you point out a very important point, that before we let P. 
O’Dwyer with his laparoscope go near any adrenal mass 
we always exclude catecholamine excess first. Irrespective 
of the imaging phenotype, some sort of assessment of cat-
echolamine production always has to be done. In terms of 
criteria to try and predict a bad outcome, obviously ENSAT 
staging it at presentation will help do that. MicroRNA-210 is 
obviously very new, and it is not something we do routinely 
in analysis of our adrenal tumors although it is something 
we could be looking to do as part of the ENSAT network. 
But certainly the briskness of the tumor, the KI-67 index, is 
one indicator which we tend to use and just the number of 
positive Weiss criteria and the size of the tumor are all useful 
markers of prognosis.
E.L. Schiffrin: Perhaps going back to primary aldosteron-
ism, would you like to comment on some of the mutations that 
occur in channels that may have a bearing on the development 
of adrenal adenomas/aldosteronomas?
E.M. Freel: Thank you. That has been a hugely bur-
geoning area in the last couple of years since the article in 
Science13 from Rick Lifton’s laboratory that showed there 
were somatic mutations in a potassium channel in about one 
third of patients with adenomatous primary aldosteronism 
and these were also identified in the germline of a small num-
ber of patients with a very rare syndrome (of familial hyper-
aldosteronism type III). Since the original article by Rick 
Lifton,13 with the help of ENSAT and other European adrenal 
tumor associations, there has been a lot of work looking at 
channels and looking at the genetics underlying adenoma-
tous primary aldosteronism. There have been mutations now 
identified in roughly 40% of tumors. KCNJ5, which was the 
original mutation discovered in Rick Lifton’s laboratory, is 
the most predominant one and it results in the loss of selec-
tivity of the potassium filter. As a result of this mutation, the 
adrenocortical cell is constantly activated and hypertrophies 
and proliferates and produces aldosterone.
There have also been mutations identified in calcium chan-
nels and in ATP channels, a huge growth area during the past 
2 to 3 years.14,15
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